HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EHP

This article was originally published in The Rose Sheet

Executive Summary

Environmental Health Perspectives is the top-ranked journal among 134 environmental sciences journals and 93 public, environmental and occupational health journals, National Institute of Environmental Health Sciences says, citing Journal Citation Reports. NIEHS also reports it will continue publishing EHP, and "will take some specific steps to further enhance the scientific quality of EHP and to reduce production costs during difficult budgetary times," such as hiring a scientist outside NIEHS to serve as editor-in-chief, dedicating more editorial space to scientific manuscripts, thereby reducing the news, commentary and announcement sections, and using "improved technologies to facilitate the scientific peer-review process and journal production. Journal also will continue its partnerships with international scientific journals, but discontinue translation services, NIEHS says...

You may also be interested in...



Biocon And Mylan's Fulphila And Insulin Plans On Track

Biocon and Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.

Pharma Has High Hopes Of Pilot On Simultaneous Advice From EU Countries

Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers. 

Indoco Aims To Leave Regulatory Woes Behind

India’s Indoco Remedies is looking for healthy revenue growth in the coming fiscal year after beating market estimates with a 70.4% year-on-year jump in after-tax profit in its financial third quarter, propelled by strong revenues from domestic and international markets.

UsernamePublicRestriction

Register

RS014041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel